ischemic cascade


Also found in: Wikipedia.

ischemic cascade

Vascular disease A series of events lasting for hrs to several days after an initial ischemic event that results in extensive necrosis and tissue damage beyond the tissue zone first affected by the initial lack of blood flow
Mentioned in ?
References in periodicals archive ?
Known as an ischemic cascade, this drop-off of oxygen results in a sudden crush of metabolic waste that damages cell membranes as well as the mitochondria, a part of the cell that generates chemical energy and is involved in cell growth and death.
New compounds protect heart cells during and after attack
Ischemic stroke initiates a generalized series of events occurring at the onset of cerebral ischemia, referred to as the ischemic cascade (Fig.
Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment
Both systems are capable for diagnosing the Ischemic Cascade, thanks to several innovative techniques that help you quantify a variety of important cardiac functions.
ALOKA to Introduce New 'ProSound' Diagnostic Ultrasound Systems at the Scientific Session 2007 of American Heart Association, 4th to 7th of November 2007 in Orlando, Florida
Intensive basic scientific research during the last two decades has given healthcare professionals an increased understanding of the ischemic cascade in the format of the precise environmental alterations involved in the pathophysiology of ischemic injury at the cellular level.
Acute ischemic stroke review
The impact of systemic blood pressure and subsidiary maintenance of cerebral perfusion pressure are basic elements of stroke pathophysiology, yet colossal research efforts have been diverted toward the more elusive goal of identifying critical molecular targets in the ischemic cascade.
Solving the mystery of blood pressure in acute stroke
Tomas Odergren, Global Product Director for NXY-059 at AstraZeneca added: "The results of SAINT I suggest that disruption of the ischemic cascade through neuroprotection, which is the proposed mechanism of action for NXY-059, could have clinical application for a broad range of patients suffering an acute ischemic stroke.
New England Journal of Medicine Publishes NXY-059 Study, the First International Study of a Neuroprotectant to Show Reduced Disability Following Acute Ischemic Stroke
Neuroprotective drugs, which boast the ability to halt the ischemic cascade, offer huge hope to sufferers, but as yet, no such compound has received US approval.
Research and Markets: Several Promising Neuroprotective Drug Compounds for Treatment of Stroke in Development
Decreased blood flow to the brain deprives the brain of oxygen, triggering the ischemic cascade that includes calcium influx, overstimulation of excitatory amino acids, and overproduction of free radicals.
Predictive value of biochemical markers in stroke
Tomas Odergren, Global Product Director for NXY-059 at AstraZeneca added, "The results of SAINT I suggest that disruption of the ischemic cascade through neuroprotection, the proposed mechanism of action for NXY-059, could have clinical application for a broad range of patients suffering an acute ischemic stroke.
New England Journal of Medicine Publishes NXY-059 Study, the First International Study of a Neuroprotectant to Show Reduced Disability Following Acute Ischemic Stroke
Prolonged ischemia results in a stereotypical series of biochemical events leading to eventual cell death, the so-called ischemic cascade.
The 5 Ps of acute ischemic stroke treatment: parenchyma, pipes, perfusion, penumbra, and prevention of complications. (Featured CME Topic: Stroke)
Fox stated: "Because of its action on fundamental cellular function, CPC-111 is the only compound that is known to act on multiple processes which contribute to the toxic ischemic cascade.
Cypros Pharmaceutical Corp. to begin Phase II trials of its cytoprotective drug CPC-111
Tomas Odergren, Global Product Director for NXY-059 at AstraZeneca added: "The results of SAINT I suggest disruption of the ischemic cascade through neuroprotection, which is the proposed mechanism of action for NXY- 059, could have clinical application for a broad range of patients suffering an acute ischemic stroke.
New England Journal of Medicine Publishes NXY-059 Study, the First International Study of a Neuroprotectant to Show Reduced Disability Following Acute Ischemic Stroke

Medical browser ?
Full browser ?